We identified that CXCL13 and galectin-9 plasma concentrations were significantly higher in CLL patients, with a median serum CXCL13 concentration of 118.0 pg/mL (range, 40.0–1290.0 pg/mL), and a median galectin-9 concentration of 653.0 pg/mL (range, 300.0–2315.0 pg/mL), compared with CXCL13 concentration of healthy controls (median, 39.5 pg/mL, range, 25.0–250.0 pg/mL) and a median galectin-9 concentration of 274.5 pg/mL (range, 160.0–450.0 pg/mL) (p value < 0.0001). Here, LGALS9 is linked to B-cell chronic lymphocytic leukemia.